WAI YUEN TONG (00897) announced its interim results for the six months ended September 30, 2025. The company recorded revenue of approximately HK$323 million, representing a 6.93% year-on-year decline. Net profit attributable to shareholders was HK$2.77 million, a sharp decrease of 88.3% compared to HK$23.70 million in the same period last year. Earnings per share stood at HK$0.0025.
The company attributed the revenue decline primarily to weaker sales performance in both traditional Chinese medicine and Western medicine/health supplement products.